Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity

Publisher： Bentham Science Publishers

E-ISSN： 2212-3962|7|1|2-9

ISSN： 1574-8901

Source： Recent Patents on Cardiovascular Drug Discovery, Vol.7, Iss.1, 2012-04, pp. : 2-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glucagon-Like Peptide 1 and the Cardiovascular System

By  

Current Diabetes Reviews, Vol. 10, Iss. 5, 2014-09 ,pp. : 302-310

Bentham Science Publishers

Access to resources Recommend Favorite

Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus

By Gallwitz Baptist  

Treatments in Endocrinology, Vol. 4, Iss. 6, 2005-01 ,pp. : 361-370

Adis International

Access to resources Recommend Favorite

Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus

By Cypryk Katarzyna   Vilsbøll Tina   Nadel Iwona   Smyczynska Joanna   Holst Jens Juul   Lewinski Andrzej  

Gynecological Endocrinology, Vol. 23, Iss. 1, 2007-01 ,pp. : 58-62

Informa Healthcare

Access to resources Recommend Favorite

Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies

By  

Current Diabetes Reviews, Vol. 12, Iss. 4, 2016-10 ,pp. : 331-358

Bentham Science Publishers

Access to resources Recommend Favorite

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy

By  

Current Diabetes Reviews, Vol. 12, Iss. 4, 2016-10 ,pp. : 403-413

Bentham Science Publishers

Access to resources Recommend Favorite